Corticosteroid-binding globulin (CBG) is a serine proteinase inhibitor (serpin) family member that transports glucocorticoids in blood and regulates their access to target cells. The 1.9 Å crystal structure of rat CBG shows that its steroid-binding site resembles the thyroxin-binding site in the related serpin, thyroxin-binding globulin, and mutagenesis studies have confirmed the contributions of key residues that constitute the steroid-binding pocket. Unlike thyroxin-bound thyroxin-binding globulin, the cortisol-bound CBG displays an "active" serpin conformation with the proteinase-sensitive, reactive center loop (RCL) fully expelled from the regulatory ␤-sheet A. Moreover, the CBG structure allows us to predict that complete insertion of the proteolytically cleaved RCL into the serpin fold occurs in concert with a displacement and unwinding of helix D that would disrupt the steroid-binding site. This allosteric coupling between RCL positioning and occupancy of the CBG steroidbinding site, which resembles the ligand (glycosamino-glycan)-dependent activation of the thrombin inhibitory serpins heparin cofactor II and anti-thrombin RCLs, ensures both optimal recognition of CBG by target proteinases and efficient release of steroid to sites of action.
Glucocorticoid hormones (cortisol and corticosterone) and progesterone are transported in the blood by a glycoprotein known as corticosteroid-binding globulin (CBG) 3 or transcortin (1) . Plasma CBG also binds several synthetic glucocorticoids, such as prednisolone (2) , and influences the half-life, distribution, and efficacy of these drugs in the same way as for natural steroids (3) . The steroid binding characteristics of CBG from many species have been documented (1) , and a benchmark set of CBG steroid binding characteristics has be used to develop three-dimensional quantitative structure activity relationship (3D-QSAR) computational methods (4, 5) aimed at predicting the binding affinities of ligands to target proteins. Although residues within CBG sequences critical for steroid binding have been identified through studies of naturally occurring variants (6 -10) , photo-affinity labeling (11) , and mutagenesis (12) , a precise picture of its structure and steroidbinding site has been lacking.
The primary structure of CBG defines it as a clade A member of the serine proteinase inhibitor (serpin) superfamily, together with the related transport protein for thyroxin, thyroxin-binding globulin (TBG), and the prototypical serpin members ␣1-antitrypsin (AAT) and ␣1-antichymotrypsin (ACT), among others (13, 14) . A hallmark of serpin structures is that they undergo conformational rearrangements as part of their biological function. The conformations they adopt are highly dependent on whether a surface-exposed loop, known as the reactive center loop (RCL) or "proteinase bait" domain, is intact. Cleavage of the RCL segment by proteinases usually causes a typical stressed to relaxed (S 3 R) transition in structure (15) . This involves insertion of the entire N-terminal segment of the RCL segment into the central A-sheet, where it forms a novel ␤-strand and triggers main chain rearrangements that affect different parts of the serpin fold.
Even though most serpin clade A members inhibit proteinases (15) , there is no evidence that CBG or TBG function in this way. By contrast, CBG and TBG appear to be suicide substrates for the elastase produced by neutrophils during inflammation, which cleaves the RCL of the serpin structure (16, 17) . In the case of CBG, this causes a pronounced alteration of its conformation that is marked by an increase in thermostability (17) , a behavior typical of serpins that undergo the S 3 R transition. In CBG, this essentially eliminates its ability to bind steroid (16, 17) and supports the hypothesis that proteinase cleavage of CBG facilitates the targeted delivery of its anti-inflammatory steroids to sites of action (18) .
Here we present the 1.9 Å resolution crystal structure of rat CBG together with mutagenesis data that confirm the roles of key residues within the steroid-binding site. In contrast to the structure of thyroxin-bound TBG, in which the RCL is partially inserted into the serpin fold (19) , the RCL of CBG in complex with cortisol is completely expelled. In this context, the position of the RCL in the steroid-bound CBG structure is very similar to the repositioning of the RCL that occurs in antithrombin and heparin cofactor II upon occupancy of their glycosaminoglycan-binding sites (20 -22) , and this suggests a similar allosteric mechanism linking ligand binding and positioning of the RCL in these related serpins. Moreover, the CBG structure indicates that full insertion of the RCL into the serpin fold can occur upon its proteolytic cleavage and that this would very effectively disrupt the steroid-binding site.
EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Crystallization-The coding sequence for residues 5-374 of the mature rat CBG polypeptide was fused in-frame with glutathione S-transferase in pGEX-2T (GE Healthcare Bio-Sciences AB, Uppsala Sweden) and expressed as a glutathione S-transferase fusion protein in Escherichia coli (strain K12 BL21). An overnight culture of a colony containing the expression construct was used to inoculate 5 liters of Luria Broth, which was incubated at 37°C until the optical density at ϭ 600 nm reached 0.5. At this point, 100 M ␤-D-thiogalactopyranoside and 10 M cortisol were added, and the cells were harvested after a 4-h incubation at 33°C. The bacterial pellet was resuspended in 80 ml of phosphate-buffered saline containing 5 mM EDTA and cooled to 6°C, when 1 mM Pefabloc was added to decrease degradation.
The recombinant protein product was extracted from the cells by five consecutive 40-s sonication steps. After centrifugation at 65,000 ϫ g and 4°C, the supernatant extract was diluted in phosphate-buffered saline buffer at a ratio of 1:10 and loaded onto a 25-ml Glutathione Sepharose HP (GE Healthcare BioSciences) affinity column at a flow rate of 0.5 ml/min. The column was rinsed with 250 ml of chromatography buffer (50 mM Tris buffer, pH 8.0, 150 mM NaCl), and the affinity matrixbound protein was then removed from the column and incubated for 8 h with bovine plasma thrombin (Sigma-Aldrich) while gently rocking the suspension at room temperature. Cleavage of the glutathione S-transferase fusion protein was halted by addition of 1 mM of Pefabloc, and the recombinant CBG was removed by repacking the affinity matrix onto a column and eluting it with chromatography buffer. As a result of thrombin cleavage, an extra Gly residue remained fused to the N terminus of CBG. The eluted protein was concentrated using the MidGee Hoop System (GE Healthcare Bio-Sciences) and further purified by size exclusion chromatography (Superdex 75) at 4°C in the same buffer. Fractions containing recombinant rat CBG were collected and concentrated to 15 mg/ml. This produced ϳ1 mg of pure recombinant protein/5 liters of culture. Prior to crystallization attempts, the protein was assayed for its steroid binding activity (see below).
Initial crystallization conditions were identified using commercial crystallization screens. After further refinement, the crystals suitable for crystallography were obtained using the hanging drop method by equilibrating a droplet containing 1 l of 15 mg/ml recombinant rat CBG and 1 l of reservoir solution (30% (w/v) polyethylene glycol 4000, 300 mM Li 2 SO 4, 100 mM Tris-HCl, pH 8.5) against 700 l of reservoir solution.
Expression and Analysis of Wild Type and Variant Rat
CBGs-A cDNA encoding the rat CBG precursor was inserted into pCDNA3 (Invitrogen) for expression in Chinese hamster ovary (CHO) cells (9) . The rat CBG cDNA in pCDNA3 was also subjected to oligonucleotide-directed mutagenesis using a QuikChange site-directed mutagenesis kit (Stratagene Inc., La Jolla, CA), and the clones were sequenced to confirm the presence of only targeted mutations. After selection in the presence of neomycin, stably transformed CHO cells were grown to near confluence in ␣-minimum essential medium (Invitrogen) containing 10% fetal bovine serum and antibiotics, and then washed twice with phosphate-buffered saline to remove fetal bovine serum, prior to the addition of serum-free HyQ PF CHO Liquid Soy TM medium. After 2-4 days, the culture medium was collected and subjected to ion exchange chromatography on a Mini Q TM fast protein liquid chromatography column (GE Healthcare Bio-Sciences) to concentrate and semipurify the CBG for analysis.
To compare the steroid binding capacities of wild type and variant rat CBGs produced by CHO cells, the amounts of semipurified CBG in different samples were first equalized by Western blot analysis (23) . The samples were then diluted appropriately for measurements of steroid binding properties using a saturation analysis method employing dextran-coated charcoal as a separation agent and [
3 H]corticosterone (42 Ci/mmol; PerkinElmer Life Sciences) as labeled ligand (9) .
Crystal Structure Determination-Diffraction data were collected from a single monoclinic rat CBG crystal at beam line BL14.1 of Free University Berlin at BESSY synchrotron, Berlin. Before flash freezing, the crystal was soaked in a cryoprotectant containing 20% ethylene glycol, 100 mM Tris-HCl, pH 8.5, 300 mM Li 2 SO 4 , and 30% (w/v) polyethylene glycol 4000. The data were collected at a wavelength of 0.9537 Å in one degree oscillations steps and covering a total rotation range of 218°. The program XDS (24) was used for data processing. The data set extends to 1.9 Å resolution and is 96.9% complete with an average redundancy of 4.7 (Table 1) . Because the sequence identity between rat CBG and human AAT is as high as 42.3%, the CBG structure could be readily solved using AAT (Protein Data Bank accession code 1QLP (25) ) as a search model in the program AMORE (26) . The initial refinement of the molecular replacement solution at a resolution of 2.0 Å yielded an R factor of 38.7% and R free of 45.8%. Upon adjustment of the sequence and several rounds of refinement with the program REFMAC (27) and manual model building in the program COOT (28), the steroid cortisol became clearly visible in difference Fourier electron density maps and was incorporated into the model. Upon further refinement and inclusion of all data to 1.9 Å resolution, water molecules could be added. Activating TLS refinement in the final refinement rounds improved the quality of the electron density and lead to the convergence of the refinement at an R factor of 21.0% and R free of 26.6%. In the final model some residues lack density for their side chains, and their side chain occupancies were set to 0.0.
The structure was validated using the program PROCHECK (29) , and the coordinates were compared with those of other serpins using the program module superimpose in COOT (28) or the program LSQKAB (27) . All of the model illustrations were drawn with the program PYMOL (30).
RESULTS AND DISCUSSION
Rat CBG Displays a Typical "Active" Serpin ConformationThe crystal structure of rat CBG in complex with cortisol was solved at 1.93 Å resolution and refined to a crystallographic R factor of 21.0% and R free of 26.6% (Table 1) , and the main chain trace identifies CBG as a typical serpin (Fig. 1) . When adhering to the common serpin nomenclature, CBG contains a fivestranded ␤-sheet A (strands s1A, s2A, s3A, s5A, and s6A), a six-stranded ␤-sheet B (strands s1B-s6B), and a four-stranded ␤-sheet C (strands s1C-s4C) together with 10 intervening ␣-helices termed hA-hJ. Whereas the helices are named sequentially in alphabetical order as they occur in the primary structure, the ␤-strands in the sheets A-C are numbered according to their topological position in the sheet.
Of residues 5-374 present in the CBG crystal, no electron density was visible for the first two residues or parts of some loop segments (i.e. residues 55-56, 158 -159, 298 -309, and 329 -338 in the RCL segment). All other residues are well defined by their electron density, and 91% cluster in the core regions of the Ramachandran diagram (Table 1) . Conformational disorder accounts for the lack of electron density for residues in the RCL and other loop segments because individual rat CBG crystals were dissolved and analyzed by SDS-PAGE (data not shown), and there was no evidence that proteolysis had occurred.
Rat CBG shares 59% sequence identity with human CBG and 42.3%, 41.5%, and 37.4% sequence identity with human AAT, ACT, and TBG, respectively, and this level of sequence identity extends over their entire primary structures. Submitting the atom coordinates of rat CBG to the DALI structural alignment server (31) shows that structural similarity matches sequence identity. Next to all clade A members listed above, the closest structural relatives include members from clades C and E (14), such as antithrombin and plasminogen activator inhibitors 1 and 2. These proteins can be superimposed onto CBG with root mean square deviations ranging between 2.3 and 2.8 Å, when considering 310 -330 C␣ atoms of the 380 residues in these proteins on average. More important than the overall structural similarity is the main chain conformation adopted by CBG in two specific regions of the molecule, namely the main chain conformation around the steroid-binding pocket (see also below), and the backbone conformation at the beginning of the RCL near the C-terminal ends of strands s3A and s5A in the central ␤-sheet A. The RCL is tethered to strand s5A, and this region undergoes large structural rearrangements during the S 3 R transition. In the CBG steroid complex, the conformations of strands s3A and s5A and the beginning of the RCL are identical to those observed in active serpin conformations (Fig. 2 ) in which the RCL is completely exposed. For example, the main chain trace within this region of CBG is identical to those of uncleaved human AAT (32) (33) (34) , thermopin (35) , and some noninhibitory serpins such as ovalbumin (36) and maspin (37) . Interestingly, the conformation of the RCL observed in CBG also resembles that of other ligand-bound serpins, such as the complex of antithrombin with a pentasaccharide ligand (21, 38) (Fig. 2B) , the binary complex of heparin cofactor II with an inactive thrombin mutant (20) , and vitronectin in complex with a native (39) or mutant form (40) of plasminogen activator inhibitor 1 or 2 (41) .
The active serpin conformation of CBG differs in several ways from that of the recently solved 2.8 Å resolution crystal structure of TBG in complex with thyroxin (19) (Fig. 2) . In the latter, the RCL is partially inserted between strands s3A and s5A and resembles the conformation observed in murine ACT (42) and antithrombin and heparin cofactor II in the absence of their glycosaminoglycan ligands (20, 38) (Fig. 2C) . The reason why the RCL is partially inserted into sheet A of some serpins is not well understood. However, it is thought that glycosaminoglycan binding to a remote site of antithrombin and heparin cofactor II triggers the expulsion of the RCL and thereby regulates the inhibitory activity of these proteins. In these serpins, allosteric coupling between these distant sites is thought to be mediated by a conformational change in helix D, which is unwound in the absence of ligands (20, 38) and is elongated by two additional turns upon occupancy of the glycosaminoglycan-binding sites (21) . This is critical to their function because this repositioning of the RCL allows it to bind and inhibit their target proteinase, thrombin (20, 38) . Interestingly, unlike the thyroxin-bound TBG structure, helix D is also elongated by two additional helical turns in the cortisol-bound CBG structure (Fig. 2) .
Essential Features of the Rat CBG Steroid-binding Site-In the rat CBG structure, cortisol binds on top of ␤-sheet B (Figs.  1 and 3 ) at almost right angles to the ␤-strands and the sheet plane. Six of the 12 CBG residues in close contact with the steroid (identified by an interatom distance of less than 4 Å) are presented by ␤-strands s2B-s5B (Fig. 4) . The other six residues are displayed by helices hA and hH, which are oriented perpendicular to each other and fence off ␤-sheet B on two sides (Fig.  4) . No steroid main chain atom interactions occur in the binding site because the steroid only interacts with residues presented by ␣-helical or ␤-strand secondary structure elements that have saturated main chain hydrogen bond donors and acceptors. In the crystal structure, the CBG steroid-binding site is almost devoid of bound water molecules, and our observation that only three water molecules bridge oxygen atoms from the steroid and the protein side chains reflects the high degree of surface complementarities between the steroid ligand and residues lining the binding site.
Of the five polar atoms in cortisol, only those oxygen atoms attached to the carbon atoms C-11 and C-20 of the steroid interact directly with CBG residues (Fig. 3) . The carbonyl oxygen at C-20 makes a hydrogen bond to Gln 224 from strand s2B and appears critical for a high affinity interaction with C-21 steroids (i.e. glucocorticoids and progesterone) because substitution of Gln 224 with alanine in rat CBG results in a complete loss of steroid binding activity (Fig. 5 ).
The precise stereochemistry of this interaction appears to be critical because hydroxylation of the carbonyl oxygen at C-20 of cortisol results in a dramatic reduction in its binding affinity to human CBG (1). The orientation of Gln 224 is influenced by close contacts to neighboring side chains such as those from Phe 234 and Ile 255 , and this may be important because substitution of Phe 234 to alanine also abolishes steroid binding (Fig. 5) .
The hydroxyl group at C-17 of cortisol comes within 3.5 Å of the C␣ atom of Lys 359 (Fig. 3) , and its side chain cannot interact with cortisol because it points away from the steroid (Fig. 3A) . This explains why cortisol binds rat CBG with an affinity similar to that of corticosterone (1), which has a carbonyl oxygen at C-17. Moreover, when CBG sequences from different species are compared, the lysine at position 359 in rat CBG is often represented by a histidine, and this may account for species differences in the relative affinities of their CBGs for these two major glucocorticoids.
The hydroxyl at C-11 of cortisol is recognized by Asp 256 from helix hH, and this likely represents a biologically important point of contact because this hydroxy-group differentiates biologically active glucocorticoids (cortisol and corticosterone) from their inactive metabolites (cortisone and deoxycorticosterone), which do not bind to CBG (1). This was confirmed by a complete loss of corticosterone binding activity when Asp 256 in rat CBG was substituted with an alanine (Fig. 5) . Another common feature of all CBG ligands is the carbonyl oxygen at C-3 of the steroid ring A, but this does not appear to make any polar contacts with residues in the rat CBG structure. It points toward the side chain of the poorly conserved Pro 14 , and it remains to be determined what impact Pro 14 may have on the steroidbinding site because an alanine substitution does not reduce the affinity of rat CBG for glucocorticoids (Fig. 5) .
A unique feature of the CBG steroid-binding site is a cation-stacking interaction (43) between the side chain of Arg 10 at the beginning of hA and Trp 362 from strand s5B. This interaction orients the indol ring of Trp 362 such that it stacks favorably against the A, B, and C rings of the steroid (Fig. 3A) .
Although the NH group of the indol ring of Trp 362 does not hydrogen bond with the steroid, substitution of this highly conserved residue within the context of human CBG completely abolishes steroid binding (12) . The key role of Arg 10 in orienting Trp 362 is evidenced by a complete loss of steroid binding activity after substitution of Arg 10 with alanine (Fig. 5) .
The CBG and TBG Ligand-binding Sites Share Similar FeaturesComparing the rat CBG structure with that recently determined for human TBG (19) shows that their ligand-binding sites share several key features. Thyroxin and cortisol bind to the same face of ␤-sheet B in TBG and CBG, respectively (Fig. 3,  C and D) . The second aromatic ring in thyroxin colocalizes with rings B and C of the steroid, and the hydroxyl and acetyl groups attached to the C-17 of cortisol bind in a similar location as the amino-propionate group of thyroxin. Thus, although the chemical structures of thyroxin and cortisol differ considerably, a similar set of residues is responsible for ligand binding in both proteins. The positions of these residues colocalize in the multiple sequence alignment (Fig. 4) , as well as in the protein tertiary structures (Fig. 3) . With the exception of Gln 224 , which is equivalent to Gln 238 in human TBG, the identity of these residues differs, but their overall physicochemical properties, such as hydrophobicity versus hydrophilicity, are conserved (Fig. 4) .
A cation-interaction is also central to ligand binding in TBG, and it occurs at the same position as in CBG (Fig. 3) . In human TBG, Arg 381 and its side chain form a direct cationinteraction with the second phenolic ring of thyroxin. By contrast, Arg 10 in rat CBG forms an intramolecular cation-interaction with Trp 361 , which then in turn stacks against the steroid ligand.
Molecular Basis for Naturally Occurring CBG Variants with Reduced Steroid Binding Affinity-Naturally occurring CBG genetic variants with reduced steroid binding affinities have been detected in humans (6 -8) , rats (9) , and mice (10) . In rodents, these coding sequence variants result in a M276I substitution in rat CBG, and a L201Q substitution in mouse CBG (Lys 200 in rat CBG), and both cause modest reductions in steroid binding affinities (9, 10) . In the rat CBG structure, Met 276 is located on the outer strand of sheet A (strand s6A), and its side chain points toward the interior of the protein where it contributes to the hydrophobic core. Although a methionine is also present at this location in mouse CBG, this is an isoleucine residue in all other CBG and related serpin sequences (data not shown), and methionine and isoleucine residues in (16, 17) , i.e. between P5 and P6 rather than immediately after P1 as in the other serpins. Also boxed in black are highly conserved residues (rat residues Leu 85 and Asp 358 ), the substitution of which in naturally occurring human CBG variants reduces steroid binding affinity (see text). this position therefore likely contribute similarly to the overall serpin structure. Lys 200 in rat CBG is conserved in most CBG sequences in the public data bases, and it is displayed from strand s2C on the protein surface where it forms salt bridges with Asp 190 and Glu 188 , which likely contribute to protein stability (44, 45) . Moreover, like Met 276 , Lys 200 is distant from steroid-binding site or the site where the RCL insertion likely occurs upon proteolytic cleavage, and substitutions at these positions probably affect steroid binding only indirectly by altering the general stability of the protein. By contrast, the common S224A human CBG variant (Ser 116 in rat CBG) binds steroid normally (8) , and this is understandable because its side chain points away from the protein surface and is not close to the steroid-binding pocket or the RCL insertion site.
A more informative picture arises when considering the human variants L93H (6 -8) and D367N (6, 7) , identified as CBG Leuven and CBG Lyon, respectively. The Leu 93 (Leu 85 in rat CBG) and Asp 367 (Asp 358 in rat CBG) are invariantly conserved in all CBG sequences determined to date and are unique to CBG structures within clade A serpins (Fig. 4) . Rat CBG Leu 85 is part of helix D and points directly toward the loop that interconnects strand s4B and the s5B strand containing Trp 362 and other residues that comprise the steroid-binding site (Fig.  6) . Moreover, strand s4B contains Asp 358 , which points directly toward Leu 85 on helix D (Fig. 6 ). We therefore predict that, although the naturally occurring substitutions of Leu 93 or Asp 367 in human CBG are not part of the steroid-binding site, they participate in an allosterically coupling mechanism linking the steroid-binding site to the RCL insertion site, as discussed below.
A Mechanism for the Irreversible Disruption of the CBG Steroid-binding Site-Under normal physiological conditions, steroid binding and dissociation from CBG is reversible and controls the relative amounts of biologically active glucocorticoids and progesterone that are either bound to other plasma proteins, such as albumin, or in a free form that can diffuse into tissues or cells (3) . At sites rich in proteinases, however, the targeted proteolysis of CBG results in an S 3 R transition of its conformation that irreversibly incapacitates the steroidbinding site (16, 17) , and the crystal structure we have obtained reveals how this can occur.
Although the crystal structure of proteolytically cleaved CBG remains to be determined, structures from other cleaved serpins allow us to predict the main structural characteristics of CBG in the R conformation (15) . During the S 3 R transition, the N-terminal portion of the RCL is expected to integrate into sheet A and produce a novel ␤-strand s4A (Fig. 6) . The sequence registration of the new ␤-strand s4A can be readily predicted because the N terminus of s4A is tethered to strand s5A via a type I ␤-turn in all cleaved serpins. The two residues at positions iϩ1 and iϩ2 of the turn are commonly labeled P17 and P16, because they occur 15-17 residues before the P1-P1Ј residues that constitute the canonical proteinase cleavage site (15) in AAT and ACT (Fig. 4) . After integration into ␤-sheet A, all even numbered residues at the beginning of s4A, namely P14, P12, P10, etc., point toward the center of the protein. Conversely, the side chains of residues P15, P13, and P11 remain surface-exposed.
Not all serpins readily integrate the RCL upon cleavage, and biochemical experiments have shown that the ability of a serpin to undergo the S 3 R transition depends crucially on the sequence of the residues P8 to P18 (15) . A careful analysis of this segment in CBGs from various species shows that it displays all the characteristics necessary to undergo this transition. In general there is a Gly residue at P15 and small, predominantly hydrophobic residues at P14, P12, P10, P9, and P8 (Fig. 4) . Although there is an asparagine at P15 in rodent CBGs, a combination of molecular modeling, energy minimization, and molecular dynamics calculations suggest that the glycine at P16 in rodent CBGs substitutes for the P15 glycine in other species (see supplemental data).
For the crystal structure of TBG (19) , it has been suggested that the proline at P8 prevents the complete insertion of the RCL because prolines do not participate in regular ␤-sheet hydrogen bonds. Although single prolines only occur at P12 within this segment of rodent CBGs and at P9 in pig and sheep CBG (Fig. 4) , we do not expect them to prevent the RCL insertion into CBG because mutating the P10 residue Gly 349 to proline in AAT did not affect its general ability to undergo an S 3 R transition (46) . In general, the kinetics of loop insertion and the inhibitory properties of serpins are sensitive to single amino acid substitutions in the RCL segment, but the S 3 R transition is abolished only when the canonical pattern of small, hydrophobic residues at P14, P12, P10, P9, and P8 is severely disrupted (15) . For instance, an arginine residue at P14 in ovalbumin precludes the S 3 R transition, whereas its substitution with threonine allows insertion of the cleaved RCL (47, 48) . We therefore conclude that all CBGs are likely to undergo an S 3 R transition upon proteolytic cleavage, which is characterized by full insertion of the RCL N-terminal region into ␤-sheet A in concert with conformational changes in remote parts of the molecule.
Helix D as the Key Element Coupling the CBG Steroid-binding Site and RCL Positioning-The shortest line connecting the RCL insertion site in sheet A and the steroid-binding site on the surface of sheet B passes through the plane of ␤-sheet B, and this is structurally significant because both sheets form extensive ␤-sandwich-like interactions in this region (Fig. 1) . However, the ␤-sheet must be considered a stable entity because of the numerous interstrand hydrogen bonds, and it seems unlikely that the interstrand interactions in sheet B are disrupted by any changes brought about by ligand binding. Indeed, when superimposing a number of serpins in the cleaved R and uncleaved S form, it becomes apparent that the geometry of sheet B is highly conserved. If this holds true for CBG, then an allosteric coupling pathway that connects the loop insertion site and the steroid-binding site must make use of residues along the rims of both ␤-sheets, instead. In this scenario, Helix D would play a key role because it runs along the rim of sheet A (Figs. 2 and 6 ) and makes numerous contacts to residues from loop segments that interconnect the strands of ␤-sheet B, namely the loops s2B-s3B and s4B-s5B (Fig. 6) , and this would be significant because s5B contains residues (Lys 359 and Trp 362 ) that are key determinants of steroid binding (Figs. 3 and 6) .
Helix D is also one of the regions of the serpin fold most severely affected by conformational changes brought about by the S 3 R transition, and this can be readily appreciated when superimposing TBG onto CBG (Fig. 2A) . In TBG, the RCL is already partially inserted into sheet A, and the conformational change in the region surrounding the insertion site is very similar to that triggered by full insertion of the cleaved RCL (strand s4A), as observed in many cleaved or latent serpin structures (15) . Moreover, strands s3A and s2A in TBG are pushed outwards, and helix D, which is tethered to strand s2A, is likewise displaced when compared with its position in CBG (Fig. 2) .
Further comparisons between CBG and other serpins suggest that the secondary structure content of helix D is likely to change during the S 3 R transition. In the crystal structure of CBG, helix D is elongated by approximately two helical turns, and in this respect the main chain conformation clearly differs from that in TBG and most other serpins (Fig.  2) . To our knowledge, a similar extension of helix D only also occurs in antithrombin and heparin cofactor II (20, 21, 38) upon binding of their glycosaminoglycan ligands to a site close to the corticosteroid-binding site in CBG. As discussed before, these serpins switch conformations in the presence and absence of their ligands. Although the RCLs of antithrombin and heparin cofactor II are fully exposed and helix D extended by two helical turns in the presence of ligands, the RCL is partially inserted into sheet A and helix D unwinds by two helical turns in the absence of ligands (20, 38) (Fig. 2) . By analogy, it is possible that the RCL is partially inserted in unliganded CBG, whereas full insertion of the RCL in cleaved CBG will almost certainly result in a similar unwinding and repositioning of helix D (Fig. 6 ). In this context, the resulting conformational changes in helix D will likely alter the steroid binding affinity of CBG because residues within helix D are in direct contact with residues in loop segments that line the steroid-binding site. It is difficult to pinpoint to the exact inter-residue contacts that might transmit any changes in helix D to the steroid-binding site, but prime candidates include Leu 85 from helix D and Asp 358 from the strand s4B (Fig. 6 ) because they reside at the interface between helix D and ␤-sheet B, and their substitution in human variants causes reductions in steroid binding affinity (6 -8). exists with a partially inserted RCL. B, steroid-bound CBG with a fully exposed RCL observed in the crystal structure. C, cleaved CBG with the RCL inserted into the central A sheet, as commonly observed in serpins that undergo an S 3 R transition. Secondary structure elements implicated in the proposed mechanism are depicted with elements that undergo conformational rearrangements in gray. The extension of helix D by additional helical turns is highlighted in B. We propose that a similar allosteric coupling mechanism, albeit triggered in opposite direction, is responsible for regulating steroid-binding in CBG and the glucosaminoglycan-dependent proteinase inhibitory activity of antithrombin. In the latter, glucosaminoglycan binding to a site close to the steroid-binding site in CBG expels the RCL of antithrombin, which is then able to inhibit thrombin (A to B). In CBG, proteinase cleavage of the RCL and concomitant S 3 R transition disrupts the steroid-binding site by the reverse mechanism (B to C). Likewise, occupancy of the CBG steroid-binding site could cause it to toggle between conformations A and B.
